anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses belongs to the fields of genetic engineering and chemistry, relating to application of 4-[(3-([(2-naphthoxo)acetyl] hydrazono) n-butyryl)amine] benzamide (FD2) in preparing antitumor medicaments. The invention provides the application of the small molecular compound 4-[(3-([(2-naphthoxo)acetyl] hydrazono) n-butyryl)amine] benzamide in preparing the antitumor medicaments. The compound can obviously inhibit the proliferation of tumor cells. FD2 is a medicament designed aiming at a cell target spot CYPJ (Cycliphilins-J) and has difficult drug resistance formation and particularly effect on tumor cells with high-expression CYPJ proteins. Therefore, the small molecular compound of the invention is developed as a new antitumor medicament with obvious tumor suppression effect and good specificity. Accordingly, the FD2 of the invention can be developed as the new antitumor medicament, therefore, the invention provides a new approach and means for treating and curing tumors.
Treatment A is 10 mg hydrocortisone (2 tablets Cortef, 5 mg each),Stress-dose will be taken per os one time 2 tablets 10 mg of Cortef 60 min before start of exercise. Cortef tablets 5 mg produced by Pharmacia and Upjohn . One day.
The adverse drug reaction profile observed in pediatric clinical trials (children and adolescents) was consistent with the adverse drug reaction profile observed in adult clinical trials. The specific adverse drug reactions observed in adult patients can be expected to be observed in pediatric patients (children and adolescents) [see Adverse Reactions (6.5)]. The most common (≥5% and twice placebo) adverse reactions observed in pediatric clinical trials include: nausea, diarrhea, decreased weight, and dizziness. 

Table 6 provides the incidence of treatment-emergent adverse reactions in MDD and GAD pediatric placebo-controlled trials that occurred in greater than 2% of patients treated with CYMBALTA and with an incidence greater than placebo. 

Other adverse reactions that occurred at an incidence of less than 2% but were reported by more CYMBALTA treated patients than placebo treated patients and are associated CYMBALTA treatment: abnormal dreams (including nightmare), anxiety, flushing (including hot flush), hyperhidrosis, palpitations, pulse increased, and tremor. 

Discontinuation-emergent symptoms have been reported when stopping CYMBALTA. The most commonly reported symptoms following discontinuation of CYMBALTA in pediatric clinical trials have included headache, dizziness, insomnia, and abdominal pain [see Warnings and Precautions (5.7) and Adverse Reactions (6.2)]. 

Growth (Height and Weight) — Decreased appetite and weight loss have been observed in association with the use of SSRIs and SNRIs. Pediatric patients treated with CYMBALTA in clinical trials experienced a 0.1kg mean decrease in weight at 10 weeks, compared with a mean weight gain of approximately 0.9 kg in placebo-treated patients. The proportion of patients who experienced a clinically significant decrease in weight (≥3.5%) was greater in the CYMBALTA group than in the placebo group (14% and 6%, respectively). Subsequently, over the 4- to 6-month uncontrolled extension periods, CYMBALTA-treated patients on average trended toward recovery to their expected baseline weight percentile based on population data from age- and sex-matched peers. In studies up to 9 months, CYMBALTA-treated pediatric patients experienced an increase in height of 1.7 cm on average (2.2 cm increase in children [7 to 11 years of age] and 1.3 cm increase in adolescents [12 to 17 years of age]). While height increase was observed during these studies, a mean decrease of 1% in height percentile was observed (decrease of 2% in children [7 to 11 years of age] and increase of 0.3% in adolescents [12 to 17 years of age]). Weight and height should be monitored regularly in children and adolescents treated with CYMBALTA.
This study is a prospective, observational and randomized study conducted between 15.07.2021 and 01.12.2021 in Ankara City Hospital Emergency Medicine Clinic, which is a third-level emergency department with approximately 450,000 patient admissions per year. Patients who applied to the emergency department and needed rapid sequential intubation were included in our study. Randomization was done according to the order of arrival of the cases. The demographic characteristics of the patients included in the study and the presence of diabetes mellitus were recorded. Routine rapid sequential intubation was performed in the standard group. In the priming group, 10% of the rocuronium dose was administered approximately 3 minutes before the induction agent. Intubation time, amount of drug used, vital signs before and after intubation, and end tidal carbon dioxide level to confirm intubation were recorded.
It will include 29 females suffering from primary dysmenorrhea. They will be asked to follow lifestyle modification advice during the program duration.
The use of Sumatriptan Injection is contraindicated in patients with ischemic or vasospastic CAD. There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of Sumatriptan Injection. Some of these reactions occurred in patients without known CAD. Sumatriptan Injection may cause coronary artery vasospasm (Prinzmetal’s angina), even in patients without a history of CAD.

Perform a cardiovascular evaluation in triptan-naive patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving Sumatriptan Injection. If there is evidence of CAD or coronary artery vasospasm, Sumatriptan Injection is contraindicated. For patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation, consider administering the first dose of Sumatriptan Injection in a medically supervised setting and performing an electrocardiogram (ECG) immediately following administration of Sumatriptan Injection. For such patients, consider periodic cardiovascular evaluation in intermittent long-term users of Sumatriptan Injection.
Program will include two 10-minute sessions/day (6 days/week) of intermittent walking (1-minute work and 1-minute rest while seated) at a prescribed speed converted into a walking cadence and followed at home using a metronome. The walking sessions will be preferably performed indoors at home or on a treadmill. During the study, 2 follow-up visits (at weeks 8 and 16) will be performed to evaluate patient adherence to the program and to update the exercise program with the duration of each session that remained constant. The walking intensity of each exercise regime will be progressively modified to increase the training load. The patients will be asked to fill out a daily training record indicating completion of the exercise and any associated symptoms. Patients will have the ability to contact the rehabilitation team, composed of a physician and a sports science expert, throughout the entire study period via phone.
The present invention provides bioactive polymer compositions that can be formulated to release a wound healing agent at a controlled rate by adjusting the various components of the composition. The composition can be used in an external wound dressing, as a polymer implant for delivery of the wound healing agent to an internal body site, or as a coating on the surface of an implantable surgical device to deliver wound healing agents that are covalently attached to a biocompatible, biodegradable polymer and/or embedded within a hydrogel. Methods of using the invention bioactive polymer compositions to promote natural healing of wounds, especially chronic wounds, are also provided. Examples of biodegradable copolymer polyesters useful in forming the blood~-compatible, hydrophilic layer or coating include copolyester amides, copolyester urethanes, glycolide-lactide copolymers, glycolide-caprolactone copolymers, poly-3-hydroxy butyrate~valerate copolymers, and copolymers of the cyclic diester monomer, 3~(S)[(alkyloxycarbonyl)methyl]-1,4-dioxane-2,5-dione, with L-lactide. The glycolide~-lactide copolymers include poly(glycolide-L-lactide) copolymers formed utilizing a monomer mole ratio of glycolic acid to L-lactic acid ranging from 5:95 to 95:5 and preferably a monomer mole ratio of glycolic acid to L-lactic acid ranging from 45:65 to 95:5. The glycolide-caprolactone copolymers include glycolide and .epsilon.-caprolactone block copolymer, e.g., Monocryl or Poliglecaprone.
The discovery of effective and safe antiobesity agents remains a challenging yet promising field. Our previous studies identified Bouchardatine derivatives as potential antiobesity agents. However, the 8a-aldehyde moiety rendered them unsuitable for drug development. In this study, we designed two series of novel derivatives to modify this structural feature. Through a structure-activity relationship study, we elucidated the role of the 8a-aldehyde group in toxicity induction. We identified compound 14d, featuring an 8a-N-acylhydrazone moiety, which exhibited significant lipid-lowering activity and reduced toxicity. Compound 14d shares a similar lipid-lowering mechanism with our lead compound 3, but demonstrates improved pharmacokinetic properties and safety profile. Both oral and injectable administration of 14d significantly reduced body weight gain and ameliorated metabolic syndrome in diet-induced obese mice. Our findings identify 14d as a promising antiobesity agent and highlight the potential of substituting the aldehyde group with an N-acylhydrazone to enhance drug-like properties.
Up to 15 adult patients who present to Duke Neurosurgery for routine seizure location using sEEG will be asked to enroll in this pilot study of ANT recording and stimulation. Once enrolled in the trial, subjects will have additional placement of two thalamic electrodes during the course of standard sEEG placement surgery. Patients routinely remain hospitalized for 7-14 days after sEEG placement, during which time their seizure medications are tapered. Continuous neural recordings are made through the sEEG electrodes for the purposes of seizure localization during the entire time the depth electrodes are in place. Up to three times daily, standard intermittent high-frequency stimulation \[130 Hertz (Hz), 90-millisecond pulse width, and 2 milliamps (mA) intensity\] will be performed with a 60-seconds on and a 300-seconds off cycle following surgery up to the entire length of sEEG monitoring.
This group will receive light cured resin-based sealant (Fissured Novo Plus). Cotton rolls and a four-handed technique will be applied for isolation. Scotchbond Universal will be rubbed in the cleaned surface for 20 seconds and air dried for 5 seconds. Afterwards, Fissured Novo Plus will be applied with a syringe. Before light-curing, the presence of air bubbles will be checked and teased out. Light curing for 40 seconds will be done. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.
This is a prospective, multicenter, randomized, cross-over, double-blind, placebo-controlled study. Patients diagnosed with advanced colorectal cancer with overt distant metastases and who will receive chemotherapy consisting of capecitabine, oxaliplatin and bevacizumab, given as 3-weekly cycles, will be randomly assigned to receive either lactobacilli (GefilusR) or placebo during the first 3 cycles of chemotherapy (for 9 weeks). Following this, the groups will be crossed over and those study participants who were allocated to lactobacilli will receive placebo for 9 weeks, and vice versa. Lactobacilli and placebo are administered twice daily. The total daily dose of lactobacilli is 20 billion CFU. The primary outcome measure is frequency of moderate/severe diarrhoea (grade 2-4). Adverse effects (including the frequency of diarrhoea, flatulence, bloating, constipation, and nausea) will be longitudinally monitored based on a patient diary and study visits. The study will also address safety and tolerability of chemotherapy, response to chemotherapy, progression-free survival, resectability of liver metastases, and serum growth factor levels. A total of 84 patients are planned to be entered.
Subjects randomly selected for the yoga group will participate in yoga classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
Patients will be approached in the clinic by a neurologist and health care professionals. The questionnaire will take place at cereneo. The group will consist of 25 participants and last between 1h. The Survey will be conducted by a clinician who will take notes. Semi-structured discussion guide will be used. With regard to the communication, the moderator will identify factors that will influence communication in a positive or negative way.

The health professionals will perform content analyses on the transcripts; the schema of categories will be oriented towards the research questions, using open questions, directly addressing quiet participants, and handling the discussion guide in a flexible way.
<P>PROBLEM TO BE SOLVED: To provide a skin aging inhibitor or improver having an excellent effect of inhibiting or improving the skin aging caused by ultraviolet rays, and to provide a cosmetic containing the same.  <P>SOLUTION: This skin aging inhibitor or improver contains (a) one, two or more kinds of extracts from plants containing isoflavone or its glycoside and (b) one, two or more kinds of extracts selected from a group comprising extracts from plants containing apigenin or its glycoside and/or plants containing procyanidin. The cosmetic contains the inhibitor or improver. An extract from soybeans, alfalfa leaves, red clover flowers, pueraria mirifica roots or white lupine seeds is exemplified as the extract from the plant containing the isoflavone or its glycoside. An extract from grapefruit seeds, perilla seeds or chamomile flowers is exemplified as the extract from the plant containing the apigenin or its glycoside. An extract from grape, apple, strawberry or cranberry fruits or seeds thereof is exemplified as the extract from the plant containing the procyanidin.  <P>COPYRIGHT: (C)2004,JPO
The present invention implements a computer-based system and procedure for the efficient and effective preparation for conducting at least one clinical trial. The various methods are deployed using a Software As A Service (“SaaS”) platform, allowing access to the system by all relevant participants. Each authorized participant in a proposed clinical trial may access a customized and customizable view of the data necessary to gain approval for conducting a clinical trial and interact with the other participants electronically, prior to initiation of a clinical trial or study. The various documents needed for the clinical trial or study, as well as the various compliance documents needed to satisfy regulatory agencies are all available for review via the Internet. By utilizing present invention, greater protection is offered for the human subjects of the clinical trials. Further, the invention offers increased productivity for sponsors, investigators, and the study participants.
Impaired Liver Function

Do not use Mibelas 24 Fe in women with acute viral hepatitis or severe (decompensated) cirrhosis of the liver [see CONTRAINDICATIONS (4)]. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Discontinue Mibelas 24 Fe if jaundice develops.

Liver Tumors

Mibelas 24 Fe is contraindicated in women with benign and malignant liver tumors [see CONTRAINDICATIONS (4)]. Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases per 100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage. 

Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (greater than 8 years) COC users. However, the attributable risk of liver cancers in COC users is less than one case per million users.
BACKGROUND: Hepatic adenomas (HAs) are benign, solid liver lesions, which carry a risk of hemorrhage and malignant transformation. This review article highlights the advances in the diagnosis and management of HAs.
METHODS: A comprehensive review was performed using MEDLINE/PubMed and Web of Science databases with a search period ending on September 30, 2023. Using PubMed, the terms "hepatocellular," "hepatic," and "adenoma" were searched.
RESULTS: HA has been classified into at least 8 subtypes based on molecular pathology, each exhibiting unique histopathologic features, clinical considerations, and risk of malignant transformation. The most common subtype is inflammatory HA, followed by hepatocyte nuclear factor 1α-inactivated HA, β-catenin exon 3-mutated HA (βex3-HA), β-catenin exon 7- or 8-mutated HA, sonic hedgehog HA, and unclassified HA. Magnetic resonance imaging is the best imaging method for diagnosis and can distinguish among HA subtypes based on fat and telangiectasia pathologic characteristics. The risk of malignant transformation varies among molecular subtypes, ranging from <1% to approximately 50%. Up to 42% of HAs present with spontaneous intratumoral hemorrhage and peritoneal hemorrhage. In general, only 15% to 20% of patients require surgery. HA larger than 5 cm are more likely to be complicated by bleeding and malignant transformation, regardless of subtype, and should generally be resected. In particular, βex3-HA carries a high risk of malignant transformation and can be considered a true precancerous lesion.
CONCLUSION: The management of HAs is based on a multidisciplinary approach. Clinical decision-making should integrate information on gender, tumor size, and HA subtyping. In the future, patients with HA will benefit from novel medical therapies tailored to the individual molecular subtypes.
1. Technical Result Increase in treatment efficiency.         2. Essence For inhibiting of thrombus formation a fibrin-specific monoclonal antibody MH-1 or an antibody produced by cells of hybridome ATCC9739 or an antibody, which is connected with the same epitope that antibody MH-1 or a fragment or a derivative of one of the mentioned antibodies, which contain the binding domain of the appropriate antibody are introduced in a person's organism. The pharmaceutical composition comprises one of the mentioned antibodies or a fragment of antibody or a derivative and pharmaceutically acceptable carrier.           3. Field of Application Medicine.
INTRODUCTION: β-Lactams are the most widely used antibiotics in children. Their optimal dosing is essential to maximize their efficacy, while minimizing the risk for toxicity and the further emergence of antimicrobial resistance. However, most β-lactams were developed and licensed long before regulatory changes mandated pharmacokinetic studies in children. As a result, pediatric dosing practices are poorly harmonized and off-label use remains common today.
AREAS COVERED: β-Lactam pharmacokinetics and dose optimization strategies in pediatrics, including fixed dose regimens, therapeutic drug monitoring, and model-informed precision dosing are reviewed.
EXPERT OPINION/COMMENTARY: Standard pediatric doses can result in subtherapeutic exposure and non-target attainment for specific patient subpopulations (neonates, critically ill children, e.g.). Such patients could benefit greatly from more individualized approaches to dose optimization, beyond a relatively simple dose adaptation based on weight, age, or renal function. In this context, Therapeutic Drug Monitoring (TDM) and Model-Informed Precision Dosing (MIPD) emerge as particularly promising avenues. Obstacles to their implementation include the lack of strong evidence of clinical benefit due to the paucity of randomized clinical trials, of standardized assays for monitoring concentrations, or of adequate markers for renal function. The development of precision medicine tools is urgently needed to individualize therapy in vulnerable pediatric subpopulations.
The invention discloses application of azelastine hydrochloride as a medicine for inhibiting the growth of colon cancer tumors. Azelastine hydrochloride is a 2, 3-phthalazinone derivative, is approved by FDA to be used for urticaria, allergic asthma, allergic rhinitis and the like, and has strong and lasting effect. The azelastine hydrochloride can be used for inhibiting the growth of colon cancer cells, and has a remarkable effect of inhibiting the growth of tumors. Most of the existing anticancer drugs are expensive, so that the use of the drugs is limited and obvious toxic and side effects are accompanied. The azelastine hydrochloride has small toxic and side effects and low price, and overcomes the defects of the existing medicines. And the azelastine hydrochloride can be combined with SN38 and Oxaliplatin traditional anticancer drugs, and the inhibition effect on the growth and proliferation of cancer cells can be obviously enhanced.
A total of 69 athletes with knee pain were recruited and randomly divided into two groups. 50 athletes completed the training programs, 25 in each group. Data was also collected from healthy athletes for normative values. International Knee Documentation Committee subjective knee evaluation form was used to report the athlete's knee condition and severity of symptoms including pain. Biodex isokinetic system was used for isokinetic and isometric strength trainings and kinetic data collection. Physical performance of an athlete was assessed by components of fitness through two commonly used tests: Illinois agility run test and vertical jump test. The athletic single leg stability test was used to assess the stability of athletes on Biodex Balance System.
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease associated with obesity and diabetes prevalence. The use of natural compounds has become an attractive approach to prevent NAFLD and its progression. Gamma-oryzanol (Orz) is a natural compound whose beneficial effects on chronic metabolic diseases have been reported. Therefore, we aimed to investigate the preventive effect of Orz on the hepatic proteome in a diet induced NAFLD model. Wistar rats were randomly distributed into three experimental groups (n=6/group) according to the diet received for 30 weeks: Control group, high sugar-fat (HSF) group, and HSF+Orz group. The isolated Orz was added to the chow at the dose of 0.5% (w/w). We evaluated the nutritional profile, characterized the presence of steatosis through histological analysis, triglyceride content in liver tissue and hepatic inflammation. Next, we performed label-free quantitative proteomics of hepatic tissue. Network analysis was performed to describe involved protein pathways. NAFLD induction was characterized by the presence of hepatic steatosis. Orz prevented lipid accumulation. The compound prevented alterations of the hepatic proteome, highlighted by the modulation of lipid metabolism, inflammation, oxidative stress, xenobiotic metabolism, and the sirtuin signaling pathway. It was possible to identify key altered pathways of NAFLD pathophysiology modulated by Orz which may provide insights into NAFLD treatment targets.
Participants will receive atezolizumab, bevacizumab, paclitaxel or pemetrexed, and carboplatin (in this order) by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with atezolizumab, bevacizumab and pemetrexed (if given in the induction phase) until unacceptable toxicity or loss of clinical benefit.